Literature DB >> 1730893

Increased risk of early measles in infants of human immunodeficiency virus type 1-seropositive mothers.

J E Embree1, P Datta, W Stackiw, L Sekla, M Braddick, J K Kreiss, H Pamba, I Wamola, J O Ndinya-Achola, B J Law.   

Abstract

An increase in illness due to measles is one of the potential consequences of the human immunodeficiency virus (HIV) epidemic in Africa. During a study of perinatal HIV transmission conducted in Kenya, the risk of acquiring measles before vaccination (9 months of age) was found to be 3.8 times higher in infants born to HIV-seropositive mothers than in control infants (10 [9%] of 109 vs. 5 [3%] of 194 infants; P = .02; odds ratio, 3.8; 95% confidence interval, 1.2-13.2). The majority of infants who developed measles in this study had significant sequelae related to their measles infection. The increased risk of measles appeared to be related to relatively lower anti-measles antibody titers detected in cord blood samples of affected infants born to HIV-seropositive mothers. However, 94% of all infants were susceptible to measles on the basis of ELISA testing at age 6 months regardless of maternal HIV serology. These observations highlight the need for improved measles vaccination strategies in Africa and for studies to delineate the effects of HIV infection on the incidence, presentation, and sequelae of childhood infectious illnesses.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730893     DOI: 10.1093/infdis/165.2.262

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Measles vaccination: Weighing the benefits and risks of a live viral vaccine for HIV-infected children.

Authors: 
Journal:  Can J Infect Dis       Date:  1996-07

Review 2.  Measles virus, immune control, and persistence.

Authors:  Diane E Griffin; Wen-Hsuan Lin; Chien-Hsiung Pan
Journal:  FEMS Microbiol Rev       Date:  2012-03-13       Impact factor: 16.408

3.  Subacute Sclerosing Panencephalitis (SSPE) in HIV Infected Child.

Authors:  Manju Kumari; Ira Shah; Naman S Shetty; Shilpa Kulkarni
Journal:  Indian J Pediatr       Date:  2020-01-14       Impact factor: 1.967

4.  Ideal age for measles vaccination with persisting maternal antibody, human immunodeficiency virus infection and protein-calorie malnutrition.

Authors:  S C Arya
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

5.  High maternal HIV-1 viral load during pregnancy is associated with reduced placental transfer of measles IgG antibody.

Authors:  Carey Farquhar; Ruth Nduati; Nancy Haigwood; William Sutton; Dorothy Mbori-Ngacha; Barbra Richardson; Grace John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2005-12-01       Impact factor: 3.731

6.  The impact of HIV/AIDS on children in developing countries.

Authors:  Joanne Embree
Journal:  Paediatr Child Health       Date:  2005-05       Impact factor: 2.253

7.  Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques.

Authors:  Chien-Hsiung Pan; Nitya Nair; Robert J Adams; M Christine Zink; Eun-Young Lee; Fernando P Polack; Manmohan Singh; Derek T O'Hagan; Diane E Griffin
Journal:  Clin Vaccine Immunol       Date:  2008-02-20

8.  Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected african children.

Authors:  Elizabeth M Obimbo; Dorothy A Mbori-Ngacha; James O Ochieng; Barbra A Richardson; Phelgona A Otieno; Rose Bosire; Carey Farquhar; Julie Overbaugh; Grace C John-Stewart
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

9.  Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.

Authors:  Kaitlin Rainwater-Lovett; Hope C Nkamba; Mwangelwa Mubiana-Mbewe; Carolyn Bolton-Moore; William J Moss
Journal:  J Infect Dis       Date:  2013-08-02       Impact factor: 5.226

10.  Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.

Authors:  Wen-Hsuan W Lin; Adrian Vilalta; Robert J Adams; Alain Rolland; Sean M Sullivan; Diane E Griffin
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.